“Regeneron Pharmaceuticals, Inc.”
🐂 Bull
- Healthcare demand is less tied to the economy
- 30% GAAP operating margin last quarter
- Free cash flow $4.1B = 28% of FY revenue
🐻 Bear
- Drug pricing, patents and regulation can reset economics
What changed
Quarter revenue $4.3B, +17% YoY; operating income $1.3B vs $1.1B a year ago (+20%).
REGN · Regeneron Pharmaceuticals, Inc.
Healthcare · ◆ Epic · Power 89/100 · CIK 0000872589
What it does
Regeneron Pharmaceuticals, Inc. is a healthcare company (pharmaceutical preparations) headquartered in NY, reporting $14.3B of revenue in its fiscal year ended 2025-12-31. Last quarter revenue moved +17% year over year with a 30% operating margin.
Auto-written from filing data.
What changed
10-Q for the period ending 2026-06-30, filed 2026-07-30 0000872589-26-000025
Quarter revenue $4.3B, +17% YoY; operating income $1.3B vs $1.1B a year ago (+20%).
- Revenue (qtr to 2026-06-30): $4.3B (+17% YoY) 0000872589-26-000025
- Operating income (qtr to 2026-06-30): $1.3B (+20% YoY) 0000872589-26-000025
- Operating cash flow (FY to 2025-12-31): $5.0B (+13% YoY) 0000872589-26-000008
🐂 Bull case
- Healthcare demand is less tied to the economy
- 30% GAAP operating margin last quarter 0000872589-26-000025
- Free cash flow $4.1B = 28% of FY revenue 0000872589-26-000008
🐻 Bear case
- Drug pricing, patents and regulation can reset economics
🚩 Red flags
- None triggered by our rules this period.
10-year history PRO
Loading…
How the power level is computed
Power (0–100) = Growth 25 × clip(quarter revenue YoY ÷ 30%) + Profit 25 × clip(quarter GAAP operating margin ÷ 30%) + Cash 20 × clip(FY free cash flow ÷ FY revenue ÷ 25%) + Fortress 15 (full if cash + short-term investments ≥ debt, else 15 × clip(1 − net debt ÷ FY revenue); half if debt isn't tagged) + Dilution 15 (full if diluted shares flat/down YoY, 0 at +5%). Missing inputs get half credit. Banks and insurers get a Financials frame: their score isn't comparable.
Not investment advice. Ticker Card summarizes public SEC EDGAR filings, which can be restated or late. No stock prices. Every number cites the filing's accession number. Source: SEC EDGAR.